{'fraction_non_alphanumeric': 0.029880478087649404, 'fraction_numerical': 0.0199203187250996, 'mean_word_length': 4.651685393258427, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
(Not Giving Up) The Marathon Race of MET Targeting Therapy: Are We There Yet?

Among the various MET aberrations, MET amplification and METex14 have emerged as valid predictive biomarkers for MET inhibition. Despite challenges that have limited the development of MET inhibitors, we can learn from the latest efforts in biomarker-based therapy to better identify the patients who will benefit from treatment with these agents. See related articles by Hong et al., p. 2403 and Van Cutsem et al., p. 2414